Systemic Therapy Clinical Trials

7 recruiting

Systemic Therapy Trials at a Glance

10 actively recruiting trials for systemic therapy are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Beijing, Beijing, and Guangzhou. Lead sponsors running systemic therapy studies include Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd., and Hutchison Medipharma Ltd.

Browse systemic therapy trials by phase

Treatments under study

About Systemic Therapy Clinical Trials

Looking for clinical trials for Systemic Therapy? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Therapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.130 enrolled1 locationNCT06122389
Recruiting
Not Applicable

Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

Gastric CancerMetastatic Gastric CancerSystemic Therapy+1 more
University Medical Center Ho Chi Minh City (UMC)250 enrolled1 locationNCT06768463
Recruiting
Phase 3

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

RadiotherapyOligoProgressive Metastatic DiseaseHepatocellular Carcinoma (HCC)+1 more
Shandong Cancer Hospital and Institute132 enrolled1 locationNCT06841172
Recruiting

Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaSystemic TherapyTransarterial Chemoembolization
Sun Yat-sen University500 enrolled1 locationNCT06788353
Recruiting
Not Applicable

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Hepatocellular CarcinomaSystemic TherapyPortal Vein Tumor Thrombus
Sun Yat-sen University42 enrolled1 locationNCT06622031
Recruiting
Not Applicable

Omission of ALND in Breast Cancer Patients With Axillary pCR

Breast CancerAxillary Lymph Node DissectionPathological Complete Response+2 more
The First Affiliated Hospital with Nanjing Medical University92 enrolled1 locationNCT05939830
Recruiting
Not Applicable

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

AblationSystemic TherapyRecurrent Hepatocellular Carcinoma+2 more
Sun Yat-sen University116 enrolled1 locationNCT06609850
Recruiting

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

Lung CancerAdvanced Hepatocellular CarcinomaOligometastasis+2 more
Sun Yat-sen University470 enrolled1 locationNCT06644430
Recruiting

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

PD-1Systemic TherapyLenvatinib+3 more
First Hospital of China Medical University84 enrolled1 locationNCT06632093
Recruiting
Phase 2

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

Histologically or cytologically documented, incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy
Hutchison Medipharma Ltd25 enrolled1 locationACTRN12613000133730